Mind Medicine (mindmed) INC

Definium Therapeutics has priced an underwritten public offering of common shares, raising approximately $805 million in gross proceeds.

Definium Therapeutics, Inc. has released an updated corporate presentation on May 19, 2026, detailing its late-stage pipeline for DT120 ODT in GAD and MDD, and DT402 for ASD, alongside its financial position and future milestones.

Definium Therapeutics has dosed the first patient in its Phase 3 Ascend study for DT120 ODT in Major Depressive Disorder, with topline data expected in 2027.

Definium Therapeutics announced significant clinical progress for its DT120 ODT program with three pivotal readouts expected in 2026.

Definium Therapeutics announced its full-year 2025 financial results, highlighting significant progress in its Phase 3 clinical programs and extending its cash runway into 2028.

Definium Therapeutics, Inc. announced the appointment of Roger Adsett to its Board of Directors, expanding the board from six to seven members.

Definium Therapeutics reported increased operating expenses and a wider net loss in Q1 2026, driven by significant investment in its DT120 and DT402 clinical programs, while advancing key trials.

Mind Medicine (MindMed) Inc. reported a significant increase in net loss and R&D expenses for Q3 2025, but bolstered its financial position with a $242.8 million capital raise post-quarter, extending its cash runway into 2028.

Mind Medicine (MindMed) Inc. reported increased net losses and cash burn in Q2 2025 as it significantly ramps up Phase 3 clinical trials for its lead product candidates, MM120 and MM402, while securing new debt financing.

MindMed's Q1 2025 results show increased R&D spending and a net loss, but the company is progressing with its clinical trials and has secured additional financing.

MindMed's Q3 2024 report highlights progress in clinical trials for MM120 and MM402, along with a strong cash position following recent financings.

MindMed's second quarter 2024 results show a net loss of $5.9 million, but the company has secured significant funding and is advancing its clinical programs.

Definium Therapeutics reports increased net losses for 2025 while progressing its lead psychedelic-based drug candidates, DT120 and DT402, into pivotal clinical trials for anxiety, depression, and autism spectrum disorder.

MindMed's 2024 10-K filing highlights advancements in clinical trials for brain health disorders, including positive results for MM120 in GAD and initiation of Phase 3 trials.

Mind Medicine (MindMed) Inc. details its share capital, voting rights, dividend policy, and regulatory compliance in its latest 10-K filing.

Definium Therapeutics Chief Legal Officer Mark Sullivan sold 13,008 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.

Brandi Roberts, Chief Financial Officer of Definium Therapeutics, Inc., sold 3,013 common shares to cover tax withholding obligations as part of a pre-established Rule 10b5-1 trading plan.

Definium Therapeutics CEO Robert Barrow sold 29,208 common shares to cover tax obligations under a Rule 10b5-1 plan.

Definium Therapeutics Chief Medical Officer Daniel Karlin sold 10,035 common shares for $45.03 per share on June 25, 2026, to cover tax withholding obligations under a Rule 10b5-1 plan.

Definium Therapeutics Chief Commercial Officer Matthew T. Wiley sold 2,867 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.

Definium Therapeutics Director Roger Crystal reports acquisition of restricted stock units and stock options, alongside beneficial ownership of common shares.

Definium Therapeutics, Inc. announced its Annual General and Special Meeting of Shareholders will be held virtually on June 11, 2026, to elect directors, appoint auditors, and approve an equity incentive plan amendment.

MindMed will hold its Annual General and Special Meeting virtually on June 12, 2025, with shareholders able to vote on key proposals including the election of directors, appointment of auditors, and approval of the 2025 Equity Incentive Plan.

MindMed announces its Annual General and Special Meeting of Shareholders to be held virtually on June 12, 2025, featuring proposals for director elections, auditor appointment, and approval of a new equity incentive plan.

Mind Medicine (MindMed) Inc. announces its 2024 Annual General and Special Meeting to be held virtually on June 10, 2024, outlining proposals for shareholder voting including the election of directors, appointment of an auditor, and approval of an employee share purchase plan.

MindMed's upcoming annual meeting on June 10, 2024, will address the election of directors, appointment of an auditor, and approval of an employee share purchase plan.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported beneficial ownership of 3,000,000 shares, representing 3.01% of Definium Therapeutics, Inc. common stock as of March 31, 2026.

Driehaus Capital Management LLC reports a 6.64% beneficial ownership stake in Definium Therapeutics, Inc., holding over 6.5 million shares.

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have disclosed a 5.08% beneficial ownership stake in Mind Medicine (MindMed) Inc. for investment purposes.

Deep Track Capital, LP and affiliates reported a 5.54% beneficial ownership stake in Definium Therapeutics, Inc. as of December 31, 2025.

Deep Track Capital and its affiliates have reported a 6.87% beneficial ownership stake in Mind Medicine (MindMed) Inc., including 4 million pre-funded warrants.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 8.19% in Mind Medicine (MindMed) Inc., totaling 6,500,000 common shares.